
GSK continues to advance the future of respiratory medicine and patient care with new data at ATS
40+ abstracts across GSK’s inhaled and respiratory biologics portfolio Additional analyses from the MATINEE trial expands body of evidence for the reduction of COPD exacerbations, emergency department visits and/or hospitalisations with mepolizumab …